Clinical Trial Update: Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating zanubrutinib in combination with rituximab for secondary hemophagocytic lymphohistiocytosis in patients with B-cell lymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Status: RECRUITING